Gilead clos­es $247M HIV drug set­tle­ment deal

A Cal­i­for­nia fed­er­al judge on Fri­day ap­proved a near­ly $247 mil­lion plan to set­tle claims that Gilead wrong­ful­ly kept gener­ic HIV com­peti­tors from the mar­ket …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER